| HOME >> MEDICINE >> TECHNOLOGY |
Symptoms of RA include joint stiffness, joint pain, inflammation of the affected areas and an associated reduction in mobility. These symptoms can be intermittent and vary in severity from patient to patient. In more severe cases RA can eventually lead to disability. RA patients are also at a higher risk of developing other conditions, in particular heart disease, stroke, infections, lung problems and osteoporosis.(7)
As there is currently no cure for RA, treatment goals center on disease management and controlling symptoms. Treatment is aimed at controlling disease progression, providing pain relief and reducing swelling, preventing joint damage and deformity and maintaining function of the affected joints to prevent disability.
Traditional treatments for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease modifying anti-rheumatic drugs (DMARDs), with biological therapies a more recent addition to the list of treatment options. Anti-TNF (TNF-alpha; Tumor Necrosis Factor) therapies are specific types of monoclonal antibodies (biological therapies) which have been used in patients with RA. They may be given alone but are usually given in combination with methotrexate or another immunosuppressant. Anti-TNF therapies have proven to be effective treatments, with the potential to prevent joint damage. They work by inhibiting the action of TNF-alpha, an inflammatory mediator, either directly or indirectly responsible for damaging the joint.(7)
About CIMZIA(R) (certolizumab pegol)
CIMZIA(R) is an investigational drug product. If approved, CIMZIA will
be the first and only PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA is
Fc- free and thus avoids potential cellular cytotoxicity in vitro. CIMZIA
has a high affinity for human TNF-alpha, selectively neutralizing t
'/>"/>
| SOURCE UCB Copyright©2007 PR Newswire. All rights reserved |